OBJECTIVES: The central issue in this study is to investigate the expression of Sex determining region Y-BOX2 (SOX2) and fibroblast growth factor receptor 1 (FGFR1), evaluate their clinicopathological variables and prognostic significance in small cell lung cancer (SCLC). METHODS: Specimens from 222 SCLC patients and 53 adjacent normal lung tissues were detected by the immunohistochemistry for SOX2 and FGFR1 expression. The relationship between the expression of both markers and survival status was determined. RESULTS: Overexpression of SOX2 and FGFR1 were revealed in SCLC tumors than in normal tissues (P<0.05). SOX2 expression was associated with clinical stage (P=0.014) and lymph node status (P=0.041). Besides, FGFR1 expression was significantly higher in ever smokers (P=0.030) and late stage SCLC (P=0.005). SOX2, FGFR1 and TNM stage were independent prognostic factors for overall survival (OS) and Recurrence-free survival (RFS) by multivariate analysis. In stage I patients, only overexpression of SOX2, but not of FGFR1, predicted poor OS (0.027) and RFS (P=0.013). According to the expression of SOX2 and FGFR1, patients were categorized into three groups. Patients with elevated expression of both markers belonged to the group with the shortest RFS (P<0.0001) and OS (P<0.0001). CONCLUSIONS: Increased expression of SOX2 and FGFR1 may be available as poor prognostic indicators in SCLC patients.
OBJECTIVES: The central issue in this study is to investigate the expression of Sex determining region Y-BOX2 (SOX2) and fibroblast growth factor receptor 1 (FGFR1), evaluate their clinicopathological variables and prognostic significance in small cell lung cancer (SCLC). METHODS: Specimens from 222 SCLCpatients and 53 adjacent normal lung tissues were detected by the immunohistochemistry for SOX2 and FGFR1 expression. The relationship between the expression of both markers and survival status was determined. RESULTS: Overexpression of SOX2 and FGFR1 were revealed in SCLC tumors than in normal tissues (P<0.05). SOX2 expression was associated with clinical stage (P=0.014) and lymph node status (P=0.041). Besides, FGFR1 expression was significantly higher in ever smokers (P=0.030) and late stage SCLC (P=0.005). SOX2, FGFR1 and TNM stage were independent prognostic factors for overall survival (OS) and Recurrence-free survival (RFS) by multivariate analysis. In stage I patients, only overexpression of SOX2, but not of FGFR1, predicted poor OS (0.027) and RFS (P=0.013). According to the expression of SOX2 and FGFR1, patients were categorized into three groups. Patients with elevated expression of both markers belonged to the group with the shortest RFS (P<0.0001) and OS (P<0.0001). CONCLUSIONS: Increased expression of SOX2 and FGFR1 may be available as poor prognostic indicators in SCLCpatients.
Entities:
Keywords:
FGFR1; SOX2; immunohistochemistry; prognosis; small cell lung cancer
Authors: Paul Maddison; Alison Thorpe; Paul Silcocks; John F R Robertson; Caroline J Chapman Journal: Lung Cancer Date: 2010-04-03 Impact factor: 5.705
Authors: Johannes Voortman; Jih-Hsiang Lee; Jonathan Keith Killian; Miia Suuriniemi; Yonghong Wang; Marco Lucchi; William I Smith; Paul Meltzer; Yisong Wang; Giuseppe Giaccone Journal: Proc Natl Acad Sci U S A Date: 2010-07-06 Impact factor: 11.205
Authors: Olivier E Pardo; John Latigo; Rosemary E Jeffery; Emma Nye; Richard Poulsom; Bradley Spencer-Dene; Nick R Lemoine; Gordon W Stamp; Eric O Aboagye; Michael J Seckl Journal: Cancer Res Date: 2009-11-10 Impact factor: 12.701
Authors: Ping Yuan; Humam Kadara; Carmen Behrens; Ximing Tang; Denise Woods; Luisa M Solis; Jiaoti Huang; Monica Spinola; Wenli Dong; Guosheng Yin; Junya Fujimoto; Edward Kim; Yang Xie; Luc Girard; Cesar Moran; Waun Ki Hong; John D Minna; Ignacio I Wistuba Journal: PLoS One Date: 2010-02-09 Impact factor: 3.240
Authors: Adam J Bass; Hideo Watanabe; Craig H Mermel; Soyoung Yu; Sven Perner; Roel G Verhaak; So Young Kim; Leslie Wardwell; Pablo Tamayo; Irit Gat-Viks; Alex H Ramos; Michele S Woo; Barbara A Weir; Gad Getz; Rameen Beroukhim; Michael O'Kelly; Amit Dutt; Orit Rozenblatt-Rosen; Piotr Dziunycz; Justin Komisarof; Lucian R Chirieac; Christopher J Lafargue; Veit Scheble; Theresia Wilbertz; Changqing Ma; Shilpa Rao; Hiroshi Nakagawa; Douglas B Stairs; Lin Lin; Thomas J Giordano; Patrick Wagner; John D Minna; Adi F Gazdar; Chang Qi Zhu; Marcia S Brose; Ivan Cecconello; Ulysses Ribeiro; Suely K Marie; Olav Dahl; Ramesh A Shivdasani; Ming-Sound Tsao; Mark A Rubin; Kwok K Wong; Aviv Regev; William C Hahn; David G Beer; Anil K Rustgi; Matthew Meyerson Journal: Nat Genet Date: 2009-10-04 Impact factor: 38.330
Authors: Erin D Pleasance; Philip J Stephens; Sarah O'Meara; David J McBride; Alison Meynert; David Jones; Meng-Lay Lin; David Beare; King Wai Lau; Chris Greenman; Ignacio Varela; Serena Nik-Zainal; Helen R Davies; Gonzalo R Ordoñez; Laura J Mudie; Calli Latimer; Sarah Edkins; Lucy Stebbings; Lina Chen; Mingming Jia; Catherine Leroy; John Marshall; Andrew Menzies; Adam Butler; Jon W Teague; Jonathon Mangion; Yongming A Sun; Stephen F McLaughlin; Heather E Peckham; Eric F Tsung; Gina L Costa; Clarence C Lee; John D Minna; Adi Gazdar; Ewan Birney; Michael D Rhodes; Kevin J McKernan; Michael R Stratton; P Andrew Futreal; Peter J Campbell Journal: Nature Date: 2009-12-16 Impact factor: 49.962
Authors: Gerhard Hamilton; Maximilian Hochmair; Barbara Rath; Lukas Klameth; Robert Zeillinger Journal: Cell Adh Migr Date: 2016-02-26 Impact factor: 3.405
Authors: José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata Journal: Mol Diagn Ther Date: 2018-04 Impact factor: 4.074
Authors: Sergey Koshkin; Anna Danilova; Grigory Raskin; Nikolai Petrov; Olga Bajenova; Stephen J O'Brien; Alexey Tomilin; Elena Tolkunova Journal: Tumour Biol Date: 2016-07-23
Authors: Sophie van Olphen; Katharina Biermann; Manon C W Spaander; Florine Kastelein; Ewout W Steyerberg; Hans A Stoop; Marco J Bruno; Leendert H J Looijenga Journal: Am J Gastroenterol Date: 2015-09-01 Impact factor: 10.864
Authors: Kazimierz Pityński; Tomasz Banas; Milosz Pietrus; Katarzyna Milian-Ciesielska; Artur Ludwin; Krzysztof Okon Journal: Int J Clin Exp Pathol Date: 2015-07-01